Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2013-09-28 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release from Ipsen, dated September 28, 2013, announcing positive results from the Phase III CLARINET® study regarding Somatuline® for the treatment of non-functional neuroendocrine tumors (NETs). It details efficacy data (progression-free survival, hazard ratios) and safety profiles, including quotes from the Principal Investigator and Ipsen's CSO. This content—announcing significant clinical trial results and providing detailed data summaries—is characteristic of a major scientific or clinical update. It is not a full Annual Report (10-K), a general Earnings Release (ER) focusing only on financials, or a simple announcement of a report publication (RPA). While it contains scientific data, it functions as a comprehensive update on R&D progress, making it most closely aligned with an Investor Presentation (IP) or a detailed scientific disclosure. Given the structure, which is a formal press release detailing study outcomes, 'Investor Presentation' (IP) is the best fit among the provided options for a detailed scientific/clinical data release aimed at investors and the market, although it is structured as a press release. Since it is a detailed disclosure of clinical trial results, it goes beyond a simple ER or AR. It is a scientific/clinical data disclosure, which often overlaps with Investor Presentations (IP) in content focus, but since it is a formal announcement of study results, it is a significant corporate disclosure. Given the options, 'Investor Presentation' (IP) captures the detailed, forward-looking, and data-heavy nature of this announcement better than other categories like ER or AR. Q3 2013
2013-09-28 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated September 26, 2013, announcing Ipsen's plan to relocate its US R&D activities to Cambridge, MA. It discusses strategic business decisions, investments, and future outlook, including forward-looking statements typical of corporate news releases. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding strategy and operations. Since it does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), and it is a substantive announcement rather than just a notice of a report publication (RPA), the most appropriate classification is the general Regulatory Filings (RNS) category, which serves as a fallback for significant, non-standard corporate news releases that are often filed with regulators.
2013-09-26 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 26, 2013, announcing a strategic operational move: the relocation of Ipsen's US R&D activities to Cambridge, Massachusetts. It discusses investment, strategic focus (peptides, endocrinology, oncology), and includes forward-looking statements and contact information for media and investors. This type of announcement, detailing a significant business development or strategic update that is not a formal financial filing (like 10-K, IR, or ER), typically falls under general corporate news or investor relations material. Since it is a formal announcement of a business decision rather than a financial result release (ER) or a presentation (IP), and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially an Investor Presentation (IP) if it were structured as such, but it reads like a press release. Given the options, and that it is a formal announcement of a strategic business change, RNS (Regulatory Filings / miscellaneous announcements) is the best fit, although it shares characteristics with an Investor Presentation (IP) in terms of audience focus. However, it lacks the typical structure of a formal presentation deck. I will classify it as RNS as it is a general corporate announcement.
2013-09-26 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 95% confidence The document is a press release dated September 17, 2013, announcing 'positive top line results' from a Phase III clinical study (ELECT®) for the drug Somatuline®. It details the study's primary endpoint achievement and mentions future presentation of comprehensive results at a symposium. This type of announcement, focusing on key clinical trial outcomes and financial/operational highlights outside of a mandatory periodic report (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it is a release of key financial/operational results (clinical trial success), it fits best under the Earnings Release (ER) category, which often encompasses preliminary results announcements before a full report is filed. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a specific regulatory filing like DIRS or DIV. It is a direct announcement of results. Q3 2013
2013-09-17 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from Ipsen dated September 17, 2013, announcing positive top-line results from a Phase III clinical study (ELECT®) for their drug Somatuline® in treating carcinoid syndrome symptoms. It details the study's primary endpoint achievement, mentions future presentation plans (at a symposium), and includes standard company and forward-looking statements. This content structure—announcing clinical trial results and future presentation plans—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/R&D news. Since it is a specific announcement of clinical trial results, it is best classified as an Earnings Release (ER) as it conveys key performance/development milestones, even if not strictly quarterly financial earnings. It is not a full financial report (10-K or IR), a transcript (CT), or a management discussion (MDA). Given the focus on announcing a major R&D milestone, ER is the most appropriate fit among the options provided for a significant, time-sensitive corporate announcement. Q3 2013
2013-09-17 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a monthly update (as of August 31, 2013) on the total number of shares and voting rights. This specific type of regular disclosure regarding share capital structure and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure. Since there is no dedicated code for 'Total Voting Rights Disclosure', the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a mandatory, periodic regulatory announcement that doesn't match the other specific definitions.
2013-09-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.